0Q77 Stock Chart & Stats
€0.54
>-€0.01(-0.18%)
At close: 4:00 PM EDT
€0.54
>-€0.01(-0.18%)
Day’s Range― - ―
52-Week Range€0.54 - €1.65
Previous CloseN/A
Volume4.00
Average Volume (3M)881.00
Market Cap
€73.25M
Enterprise Value€55.46M
Total Cash (Recent Filing)€10.18M
Total Debt (Recent Filing)€4.24M
Price to Earnings (P/E)―
Beta0.32
Next Earnings
Sep 25, 2026EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding73,251,990
10 Day Avg. Volume79
30 Day Avg. Volume881
Financial Highlights & Ratios
PEG Ratio0.73
Price to Book (P/B)-5.48
Price to Sales (P/S)80.33
P/FCF Ratio-20.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.15
Revenue Forecast (FY)€1.20M
Bulls Say, Bears Say
Bulls Say
Focused Lead Asset (masitinib) Across Multiple IndicationsAB Science's lead asset, masitinib, targets multiple therapeutic areas. A single, well-characterized candidate pursued across oncology and inflammatory/neurological indications can create several potential commercial pathways, leverage existing safety and PK data, and concentrate R&D spend for durable upside if trials succeed.
Positive Revenue Growth TrendRevenue has shown consistent improvement, with reported growth and a notable 2025 uptick (~14%). Sustained revenue growth, even from a small base, indicates emerging commercial traction or milestone receipts and can modestly extend runway and validate parts of the development strategy over coming months.
Material Debt Reduction By 2025Sharp reduction in debt lowers financing costs and near-term creditor pressure, improving solvency metrics and operational flexibility. This structural deleveraging reduces default risk and frees capacity for R&D or partnering moves, strengthening the balance sheet over the medium term.
Bears Say
Persistently Negative Shareholder EquityNegative shareholder equity across reported years is a structural solvency red flag. It erodes financial resilience, constrains access to traditional financing, increases reliance on dilutive capital or partnerships, and leaves the company vulnerable to shocks absent sustained profitability or external recapitalization.
Resumed Cash Burn In 2025The return to significant negative operating and free cash flow in 2025 signals renewed funding needs. Persistent negative cash generation increases likelihood of dilution or debt financing, elevates liquidity risk, and creates a multi-month to multi-quarter structural headwind until cash flow turns sustainably positive.
Deep Recurring Net LossesChronic, sizeable operating and net losses undermine long-term sustainability. Continued negative profitability depletes resources, keeps shareholder equity negative, and makes future commercial success and financing outcomes binary for investors, imposing structural pressure until break-even or significant financing occurs.
AB Science SA News
0Q77 FAQ
What was AB Science SA’s price range in the past 12 months?
AB Science SA lowest share price was €0.54 and its highest was €1.65 in the past 12 months.
What is AB Science SA’s market cap?
AB Science SA’s market cap is €73.25M.
When is AB Science SA’s upcoming earnings report date?
AB Science SA’s upcoming earnings report date is Sep 25, 2026 which is in 46 days.
How were AB Science SA’s earnings last quarter?
AB Science SA released its earnings results on May 13, 2026. The company reported -€0.07 earnings per share for the quarter, the consensus estimate of -€0.07 by €0.
Is AB Science SA overvalued?
According to Wall Street analysts AB Science SA’s price is currently Overvalued.
Does AB Science SA pay dividends?
AB Science SA pays a Notavailable dividend of €0.285 which represents an annual dividend yield of N/A. See more information on AB Science SA dividends here
What is AB Science SA’s EPS estimate?
AB Science SA’s EPS estimate is -0.07.
How many shares outstanding does AB Science SA have?
AB Science SA has 73,251,990 shares outstanding.
What happened to AB Science SA’s price movement after its last earnings report?
AB Science SA reported an EPS of -€0.07 in its last earnings report, expectations of -€0.07. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of AB Science SA?
Currently, no hedge funds are holding shares in GB:0Q77
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
AB Science SA
AB Science S.A. is a pharmaceutical company dedicated to the discovery, development, and commercialization of protein kinase inhibitors for applications in both human and animal health. Its primary drug candidate, masitinib, a tyrosine kinase inhibitor, is currently undergoing late-stage (Phase III) clinical investigations for a range of serious conditions including prostate cancer, pancreatic cancer, amyotrophic lateral sclerosis (ALS), multiple sclerosis, Alzheimer's disease, severe asthma, and mastocytosis. Additionally, masitinib is being evaluated in Phase II clinical trials for the treatment of Covid-19. The company's pipeline also features AB8939, a synthetic microtubule destabilizer aimed at treating acute myeloid leukemia, and AB20001, which is in Phase 2 trials to assess the safety and efficacy of masitinib combined with isoquercetin in hospitalized patients experiencing moderate to severe COVID-19. Masitinib is sold under the brand name Masivet in the European market. AB Science S.A. was founded in 2001 and is based in Paris, France.